Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome

Anticancer Research

Volumn 19, Issue 2 B, 1999, Pages 1401-1405

  Gadducci, Angiolo ^a   Ferdeghini, Marco ^b   Fanucchi, Antonio ^b   Annicchiarico, Carmela ^b   Ciampi, Barbara ^b   Prontera, Concetta ^b   Genazzani, Andrea Riccardo ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Angiogenesis; Ovarian cancer; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASCITES; BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; COMBINED MODALITY THERAPY; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033061333     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992.
2. Arbiser J: Angiogenesis and the skin: A primer. J Am Acad Dermatol 34: 486-487, 1996.
3. Folkman J: What is the evidence that the tumors are angiogenesis dependent? (Editorial) J Natl Cancer Inst 82: 4-6, 1989.
4. Gasparini G, and Harris AL: Clinical importance of the determination of tumor angiogenesis in breast cancer: Much more than a new prognostic tool (Review). J Clin Oncol 13: 765-782, 1995.
5. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage SH, and Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
6. Weidner N, Sempler JP, Welch WR, and Folkman J: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
7. Brawer MK, Deering RE, Brown M, Preston SD, and Bigler SA: Predictors of pathologic stage in prostate carcinoma. The role of neovascularity. Cancer 73: 678-687, 1994.
8. Barbareschi M, Weidner N, Gasparini G, Morelli L, Eccher H, Fina P, Leonardi E, Mauri F, Bevilacqua P, and Dalla Palma P: Microvessel density quantification in breast carcinomas: Assessment by manual vs. a computer-assisted image analysis system Appl Immunohistochem 3: 75-84, 1995.
9. Fontanini G, Del Mastro L, and Bevilacqua G: Determination of angiogenesis in human neoplasms: Current prognostic and therapeutic implications. Forum 8: 128-142, 1998.
10. Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KC, and Mason DJ: Heterogeneity of vascular endothelial cell with relevance to diagnosis of vascular tumors. J Clin Pathol 45: 143-148, 1992.
11. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, and Harris AL: Angiogenesis assessed by platelet-endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
12. Schlingemann RO, Rietveld FJ, de Waal RM, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, and Ruiter DJ: Leucocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 6: 690-696, 1990.
13. Weidner N, and Folkman J. Tumor vascularity as a prognostic factor in cancer. In: "Oncology" (DeVita VT jr, Hellman S, and Rosemberg SA Eds), Philadelphia, Lippincott-Raven, p. 167-190, 1996.
14. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, and Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88: 1764-1769, 1996.
15. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, and Harris AL: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89: 1044-1049, 1997.
16. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, and Bevilacqua G: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. J Natl Cancer Inst 89: 881-886, 1997.
17. Apolinario RM, van der Valk P, de Jong JS, Deville W, van ArkOtte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM, and Giaccone G: Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456-2466, 1997.
18. Araya M, Terashima M, Takagane A, Abe K, Nishizuka S, Yonezawa H, Irinoda T, Nakaya T, and Saito K: Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol 65: 232-236, 1997.
19. Silberman MA, Partin AW, Veltri RW, and Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997.
20. Leon SP, Folkerth RD, and Blach PM: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77: 362-372, 1996.
21. Bremer GL, Tiebosch AT, van der Putten HW, Schouten HJ, de Haan J, and Arends JW: Tumor angiogenesis: An independent prognostic parameter in cervical cancer. Am J Obstet Gynecol 174: 126-131, 1996.
22. Dellas A, Moch H, Schultheiss E, Feichter G, Almendral AC, Gudat F, and Torhost J: Angiogenesis in cervical neoplasia: Microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. Gynecol Oncol 67: 27-33, 1997.
23. Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, Saito T, Kawauchi S, Tsuneyoshi M, and Nakano H: Angiogenesis in endometrial carcinoma. Cancer 80: 741-747, 1997.
24. Hollingsworth HC, Kihn EC, Steinberg SM, Rothenberg ML, and Merino MJ: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147: 33-41, 1995.
25. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radaelli U, Di Bacco A, Guglielmi RB, and Bevilacqua P: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69: 205-211, 1996.
26. Abulafia O, Triest WE, and Sherer DM: Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 177: 541-547, 1997.
27. Senger DR, Brown LF, Claffey KP, and Dvorak HF: Vascular permeability factor, tumor angiogenesis, and stroma generation. Invasion Metastasis 14: 385-394, 1995.
28. Folkman J: Clinical application research on angiogenesis. New Engl J Med 333: 1757-1763, 1995.
29. Burgess WH, and Maciag T: The heparin-hinding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58: 575-606, 1989.
30. Gospodarowicz D, Ferrara N, Schweigerer L, and Neufeld G: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8: 95-114, 1987.
31. Folkman J, and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
32. Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, and Eidsvoog K: Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 55: 277-284, 1994.
33. Di Blasio AM, Carniti C, Vigano P, and Vignali M: Basic fibroblast growth factor and ovarian cancer. J Steroid Biochem Mol Biol 53: 375-379, 1995.
34. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, and Levy BZ: Vascular endothelial growth factor and its receptors. Progr Growth Factor Res 5: 89-97, 1994.
35. Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, Tsujimura T, Sato B, Terano H, Fujiwara H, and Hamaoka T: Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 87: 963-971, 1996.
36. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, and Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516, 1995.
37. Doldi N, Bassan M, Gulisano M, Broccoli V, Boncinelli E, and Ferrari A: Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol Endocrinol 10: 375-382, 1996.
38. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, and Volm M: Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 17: 621-624, 1997.
39. Li V, Yu C, Rupnick M, Alfred E, Sallan S, Hayes DF, and Folkman J: Serum from breast cancer patients contains proliferative activity for capillary endothelial cells which correlates with risk of mortality. Proc Am Soc Clin Oncol 12: 113, 1993 (abstract 252).
40. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Footer C, Martin M, and Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76: 238-243, 1997.
41. Maggino T, Gadducci A, Romagnolo C, Fanucchi A, and Fioretti P: Times and sites of relapses after negative second-look in advanced epithelial ovarian cancer. Eur J Surg Oncol 20: 146-150, 1994.
42. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, and Cristofani R: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: Results of a multicentric Italian study. Gynecol Oncol 58: 42-47, 1995.
43. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, and Brown LF: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105-1115, 1996.
44. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, and Ramakrishnan S: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106, 1997.
45. Kamat BR, Brown LF, Manseau SJ, Senger DR and Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 146: 157-165, 1995.
46. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
47. Nagy JA, Morgan ES, Herzberg KT, Marseau EJ, Dvorak AM, and Dvorak HF: Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55: 376-385, 1995.